scholarly journals Immunoglobulin G Subclass Profile of Antimeasles Response in Vaccinated Children and in Adults with Measles History

2005 ◽  
Vol 12 (7) ◽  
pp. 845-847 ◽  
Author(s):  
Anna P. Toptygina ◽  
Alexander L. Pukhalsky ◽  
Vladimir A. Alioshkin
Keyword(s):  
Immunoglobulin G ◽  
Natural Infection ◽  
Igg Subclass ◽  
Igg Antibodies ◽  
Serum Samples ◽  
Humoral Immune ◽  
Specific Immunoglobulin ◽  
Specific Igg ◽  
Adult Volunteers ◽  
Immunoglobulin G Subclass

ABSTRACT The aim of this study was to investigate measles-specific immunoglobulin G (IgG) subclass profile in vaccinated children and in adults with natural infection. Serum samples were collected before and 30 days after vaccination. The sera from 51 late convalescent adults and seven adults with natural measles infection at the 12th day after onset of rash have been also investigated. Measles IgG antibodies and specific IgG subclasses were tested by enzyme-linked immunosorbent techniques. In children younger than 3 years, the predominant subclass was IgG3, which contributed, on average, 63.3% of the total IgG response. The contributions of specific IgG1 and IgG4 to the total IgG antimeasles response were lower (19.9% and 16.8%, respectively), whereas IgG2 was not found. In contrast, in the group of children older than 4 years, just IgG2 was a predominant subclass; it contributed 42.6% of the total IgG response. Other subclasses were also present but the contribution was much lower. In adult volunteers with measles history, IgG2 was a predominant subclass of total IgG. Thus, in early convalescence IgG2 contributed 62% of the total IgG response, whereas in late convalescence the contribution was lower (41.4%). There were no visible differences in IgG subclass composition between subjects with natural infection and vaccinated children except those below 3 years of age. The humoral immune response of such subjects is immature and the IgG2 subclass of virus-specific antibodies has not been revealed in the sera.

scholarly journals COMPARISON WITH INTENSITY OF SECONDARY DENGUE INFECTION BY DETECTING DENGUE-SPECIFIC IMMUNOGLOBULIN G ANTIBODIES

2018 ◽  
Vol 11 (12) ◽  
pp. 120
Author(s):  
Sudipta Poddar ◽  
Amiya Kumar Hati
Keyword(s):  
Immunoglobulin G ◽  
West Bengal ◽  
Dengue Infection ◽  
Hemorrhagic Fever ◽  
Igg Antibodies ◽  
Serum Samples ◽  
Specific Immunoglobulin ◽  
Specific Igg ◽  
Objective Detection ◽  
The City

Objective: Detection of dengue-specific immunoglobulin G (IgG) antibodies in the serum of healthy individuals signifies previous dengue infection. This phenomenon can be utilized to demonstrate dengue activity in a suspected area and to stratify intensity of infection in the urban and rural surroundings.Methods: Serum samples of altogether 881 healthy volunteers, 560 persons living in the central part of the city Kolkata and 321 individuals residing at a village Memari (highly endemic for dengue), 85 Km away from Kolkata, having no apparent proof of dengue activity were examined for the detection of dengue-specific IgG antibodies.Results: Of 560 serum samples collected from Kolkata, 55.5% (249) were IgG reactive. Respective figures for Memari were 321 and 25.3% (81). This indicated that the virus was also active at rural area, though the endemic property was lower than in Kolkata. In both urban (r=−0.585, p=0.017) and rural (r=−0.392, p=0.013) West Bengal, the suspected and IgG reactive cases apparently negatively correlated with age, but the percentage of reactivity was found to increase with age. The number of IgG reactive cases was significantly more in Kolkata than at Memari, indicating that dengue virus was active at Memari though the endemic property was much lower than that of Kolkata and chances of secondary dengue infection vis-a-vis dengue hemorrhagic fever would be more in Kolkata than at Memari.Conclusion: Evaluation of IgG specific dengue antibodies can be utilized to compare intensity of secondary dengue infection vis-a-vis DHF and its endemic property in different places, furnish a preliminary idea.

scholarly journals Development of a Rapid and Convenient Method for Determination of Rubella Virus-Specific Immunoglobulin G Avidity

2007 ◽  
Vol 14 (11) ◽  
pp. 1416-1419 ◽  
Author(s):  
Christelle Vauloup-Fellous ◽  
Jessica Ursulet-Diser ◽  
Liliane Grangeot-Keros
Keyword(s):  
Immunoglobulin G ◽  
Rubella Virus ◽  
Primary Infection ◽  
Virus Infections ◽  
Serum Samples ◽  
Igg Avidity ◽  
Specific Immunoglobulin ◽  
Specific Igg ◽  
Semiautomated Method

ABSTRACT We describe here a rapid and semiautomated method for the determination of rubella virus immunoglobulin G (IgG) avidity with the VIDAS instrument. A total of 153 serum samples from persons with naturally acquired rubella virus infections (n = 98), from vaccinated persons (n = 44), and from patients with autoantibodies (n = 11) were included in this study. The rubella virus-specific IgG avidity assay we developed for the VIDAS instrument was evaluated by comparison with an in-house method. Results obtained with the VIDAS instrument allow considering this method valuable to help confirm or exclude acute primary infection or recent vaccination.

Immunoglobulin G (IgG) and IgG subclass reference intervals in children, using Optilite® reagents

2018 ◽  
Vol 56 (8) ◽  
pp. 1319-1327 ◽  
Author(s):  
Olivier Grunewald ◽  
Benjamin Lopez ◽  
Séverine Brabant ◽  
Stéphanie Rogeau ◽  
Antoine Deschildre ◽  
...  
Keyword(s):  
Immunoglobulin G ◽  
Age Groups ◽  
Reference Intervals ◽  
Igg Subclasses ◽  
Specific Reference ◽  
Igg Subclass ◽  
Serum Samples ◽  
Gender Specific Differences ◽  
Specific Igg ◽  
Changes Over Time

Abstract Background: Immunoglobulin G (IgG) and IgG subclass assays are indicated in patients with suspected primary immunodeficiency (PID). Commercially available assays for IgG subclass determination are calibrated against various preparations, and so specific reference values are required for each of them. Using Optilite® reagents from The Binding Site Group Ltd., we sought to determine the pediatric IgG and IgG subclass reference intervals with respect to the ERM-DA470k certified reference material. Methods: Levels of IgG and IgG subclasses were analyzed in serum samples collected from a large cohort of PID-free children and adolescents. Reference intervals were calculated for previously published age groups (6–12 months, 12–18 months, 18 months–2 years, 2–3 years, 3–4 years, 4–6 years, 6–9 years, 9–12 years and 12–18 years), according to the Clinical and Laboratory Standards Institute’s C28-A3c protocol. Results: A total of 456 serum samples were analyzed. The correlation between the total IgG and the sum of the IgG subclasses was good (r2=0.96). No statistically significant gender-specific differences were observed. Our results for the changes over time in IgG and IgG subclass levels are consistent with previous reports. The differences between our lower/upper reference limits and those in the literature are probably due to variations in calibration. Conclusions: Our present results provide a reliable basis for the diagnosis of PIDs in childhood and for the accreditation of laboratories using Optilite® immunoturbidimetric reagents for IgG subclass measurement. Laboratory scientists and clinicians should be aware of the need for manufacturer-specific IgG subclass reference intervals.

scholarly journals Differential Decline in Leishmania Membrane Antigen-Specific Immunoglobulin G (IgG), IgM, IgE, and IgG Subclass Antibodies in Indian Kala-Azar Patients after Chemotherapy

1999 ◽  
Vol 67 (12) ◽  
pp. 6663-6669 ◽  
Author(s):  
Khairul Anam ◽  
Farhat Afrin ◽  
Dwijadas Banerjee ◽  
Netai Pramanik ◽  
Subhasis K. Guha ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Immunoglobulin G ◽  
Fold Increase ◽  
Igg Subclasses ◽  
Igg Subclass ◽  
Kala Azar ◽  
Specific Immunoglobulin ◽  
Strong Stimulation ◽  
Specific Igg ◽  
Stimulation Of

ABSTRACT Pathogenesis in kala-azar is associated with depressed cellular immunity and significant elevation of antileishmanial antibodies. Since these antibodies are present even after cure, analysis of the parasite-specific isotypes and immunoglobulin G (IgG) subclasses in kala-azar patients may shed new light on the immune responses during progression and resolution of infection. Using leishmanial membrane antigenic extracts, we investigated the relative levels of specific IgG, IgM, IgA, IgE, and IgG subclasses in Indian kala-azar patient sera during disease, drug resistance, and cure. Acute-phase sera showed strong stimulation of IgG, followed by IgE and IgM and lastly by IgA antibodies. IgG subclass analysis revealed expression of all of the subclasses, with a predominance of IgG1 during disease. Following sodium stibogluconate (SAG) resistance, the levels of IgG, IgM, IgE, and IgG4 remained constant, while there was a decrease in the titers of IgG2 and IgG3. In contrast, a significant (2.2-fold) increase in IgG1 was observed in these individuals. Cure, in both SAG-responsive and unresponsive patients, correlated with a decline in the levels of IgG, IgM, IgE, and all of the IgG subclasses. The stimulation of IgG1 and the persistence, most importantly, of IgE and IgG4 following drug resistance, along with a decline in IgE, IgG4, and IgG1 with cure, demonstrate the potential of these isotypes as possible markers for monitoring effective treatment in kala-azar.

scholarly journals Long-Term Persistence of IgG Antibodies in SARS-CoV Infected Healthcare Workers

2020 ◽  
Author(s):  
Xiaoqin Guo ◽  
Zhongmin Guo ◽  
Chaohui Duan ◽  
Zeliang Chen ◽  
Guoling Wang ◽  
...  
Keyword(s):  
Healthcare Workers ◽  
Limited Information ◽  
Igg Antibodies ◽  
Serum Samples ◽  
Humoral Immune ◽  
Humoral Immune Responses ◽  
Time Of Infection ◽  
Specific Igg ◽  
High Level

ABSTRACTBACKGROUNDThe ongoing worldwide outbreak of the 2019-nCoV is markedly similar to the severe acute respiratory syndrome (SARS) outbreak 17 years ago. During the 2002-2003 SARS outbreak, healthcare workers formed a special population of patients. Although virus-specific IgG play important roles in virus neutralization and prevention against future infection, limited information is available regarding the long term persistence of IgG after infection with SARS-like coronavirus.METHODSA long-term prospective cohort study followed 34 SARS-CoV-infected healthcare workers from a hospital with clustered infected cases during the 2002-2003 SARS outbreak in Guangzhou, China, with a 13-year follow-up. Serum samples were collected annually from 2003-2015. Twenty SARS-CoV-infected and 40 non-infected healthcare workers were enrolled in 2015, and their serum samples were collected. All sera were tested for IgG antibodies with ELISA using whole virus and a recombinant nucleocapsid protein of SARS-CoV, as a diagnostic antigen.RESULTSAnti SARS-CoV IgG was found to persist for up to 12 years. IgG titers typically peaked in 2004, declining rapidly from 2004-2006, and then continued to decline at a slower rate. IgG titers in SARS-CoV-infected healthcare workers remained at a significantly high level until 2015. Patients treated with corticosteroids at the time of infection were found to have lower IgG titers than those without.CONCLUSIONSIgG antibodies against SARS-CoV can persist for at least 12 years. The presence of SARS-CoV IgG might provide protection against SARS-CoV and other betacoronavirus. This study provides valuable information regarding humoral immune responses against SARS-CoV and the 2019-nCoV.

scholarly journals Endogenously Produced SARS-CoV-2 Specific IgG Antibodies May Have a Limited Impact on Clearing Nasal Shedding of Virus during Primary Infection in Humans

Viruses ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 516
Author(s):  
Shuyi Yang ◽  
Keith R. Jerome ◽  
Alexander L. Greninger ◽  
Joshua T. Schiffer ◽  
Ashish Goyal
Keyword(s):  
Production Rate ◽  
Neutralizing Antibodies ◽  
Primary Infection ◽  
Natural Infection ◽  
Viral Clearance ◽  
Clinical Severity ◽  
Igg Antibodies ◽  
Igm Antibodies ◽  
Specific Igg ◽  
Specific Igg Antibodies

While SARS-CoV-2 specific neutralizing antibodies have been developed for therapeutic purposes, the specific viral triggers that drive the generation of SARS-CoV-2 specific IgG and IgM antibodies remain only partially characterized. Moreover, it is unknown whether endogenously derived antibodies drive viral clearance that might result in mitigation of clinical severity during natural infection. We developed a series of non-linear mathematical models to investigate whether SARS-CoV-2 viral and antibody kinetics are coupled or governed by separate processes. Patients with severe disease had a higher production rate of IgG but not IgM antibodies. Maximal levels of both isotypes were governed by their production rate rather than different saturation levels between people. Our results suggest that an exponential surge in IgG levels occurs approximately 5–10 days after symptom onset with no requirement for continual antigenic stimulation. SARS-CoV-2 specific IgG antibodies appear to have limited to no effect on viral dynamics but may enhance viral clearance late during primary infection resulting from the binding effect of antibody to virus, rather than neutralization. In conclusion, SARS-CoV-2 specific IgG antibodies may play only a limited role in clearing infection from the nasal passages despite providing long-term immunity against infection following vaccination or prior infection.

scholarly journals Declining Levels of Neutralizing Antibodies Against SARS-CoV-2 in Convalescent COVID-19 Patients One Year Post Symptom Onset

2021 ◽  
Vol 12 ◽  
Author(s):  
Tiandan Xiang ◽  
Boyun Liang ◽  
Yaohui Fang ◽  
Sihong Lu ◽  
Sumeng Li ◽  
...  
Keyword(s):  
Symptom Onset ◽  
Neutralizing Antibodies ◽  
Natural Infection ◽  
Protein S ◽  
Igg Antibodies ◽  
Neutralizing Activity ◽  
Specific Igg ◽  
One Year ◽  
Kinetics Of

Major advances have been made in understanding the dynamics of humoral immunity briefly after the acute coronavirus disease 2019 (COVID-19). However, knowledge concerning long-term kinetics of antibody responses in convalescent patients is limited. During a one-year period post symptom onset, we longitudinally collected 162 samples from 76 patients and quantified IgM and IgG antibodies recognizing the nucleocapsid (N) protein or the receptor binding domain (RBD) of the spike protein (S). After one year, approximately 90% of recovered patients still had detectable SARS-CoV-2-specific IgG antibodies recognizing N and RBD-S. Intriguingly, neutralizing activity was only detectable in ~43% of patients. When neutralization tests against the E484K-mutated variant of concern (VOC) B.1.351 (initially identified in South Africa) were performed among patients who neutralize the original virus, the capacity to neutralize was even further diminished to 22.6% of donors. Despite declining N- and S-specific IgG titers, a considerable fraction of recovered patients had detectable neutralizing activity one year after infection. However, neutralizing capacities, in particular against an E484K-mutated VOC were only detectable in a minority of patients one year after symptomatic COVID-19. Our findings shed light on the kinetics of long-term immune responses after natural SARS-CoV-2 infection and argue for vaccinations of individuals who experienced a natural infection to protect against emerging VOC.

scholarly journals Assignment of Weight-Based Antibody Units for Seven Additional Serotypes to a Human Pneumococcal Standard Reference Serum, 007sp

2015 ◽  
Vol 22 (11) ◽  
pp. 1154-1159 ◽  
Author(s):  
D. Goldblatt ◽  
C. Y. Tan ◽  
P. Burbidge ◽  
S. McElhiney ◽  
L. McLaughlin ◽  
...  
Keyword(s):  
Polysaccharide Vaccine ◽  
Enzyme Linked Immunosorbent Assay ◽  
Reference Standard ◽  
Concordance Correlation ◽  
Clinical Protocol ◽  
Serum Samples ◽  
Reference Serum ◽  
Specific Igg ◽  
Standard Serum ◽  
Adult Volunteers

ABSTRACTThe pneumococcal enzyme-linked immunosorbent assay (ELISA) reference standard serum, lot 89SF, has been in use since 1990 and was replaced in 2013 with a new reference standard, 007sp, that is projected to be available for the next 25 years. 007sp was generated under an FDA-approved clinical protocol; 278 adult volunteers were immunized with the 23-valent unconjugated polysaccharide vaccine Pneumovax II, and a unit of blood was obtained twice from each immunized subject within 120 days following immunization. Pooled serum was prepared from the plasma of 262 subjects, filled at 6 ml per vial, and lyophilized. Five independent laboratories participated in bridging the serotype-specific IgG assignments for 89SF to the new reference standard, 007sp, to establish equivalent reference values for 13 pneumococcal capsular serotypes (1,3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) by using the WHO reference ELISA. In a second study involving three laboratories, a similar protocol was used to assign weight-based IgG concentrations in micrograms per ml to 007sp of seven serotypes (8, 10A, 11A, 12F, 15B, 22F, and 33F) also present in the 23-valent pneumococcal unconjugated polysaccharide vaccine. In addition, the IgG assignments for a 12-member WHO quality control (QC) serum panel were also extended to cover these seven serotypes. Agreement was excellent, with a concordance correlation coefficient (rc) of >0.996 when each laboratory was compared to the assigned values for the 12 WHO QC serum samples. There are four remaining pneumococcal serotypes (2, 9N, 17F, and 20) found in Pneumovax II for which IgG assignments exist for 89SF and remain to be bridged.

Sign in / Sign up

Export Citation Format

Share Document